Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia
Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), today announced that it has successfully completed …